Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mereo Biopharma Group Plc ADR (NQ: MREO )

3.605 +0.045 (+1.26%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mereo Biopharma Group Plc ADR

< Previous 1 2 3 4 Next >
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Why Ultragenyx Pharma Stock Is Trading Higher Premarket Today
Via Benzinga
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! 
Via InvestorPlace
Mereo BioPharma to Present at the Jefferies Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
From Mereo BioPharma Group plc
Via GlobeNewswire
Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on Friday. 
Via Benzinga
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical... 
Via Benzinga
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
From Mereo BioPharma Group plc
Via GlobeNewswire
Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan
From Rubric Capital Management LP
Via Business Wire
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
From Mereo BioPharma Group plc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.